ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Oct 25, 2021 19:00 JST
Source:
Genetec Technology Bhd
Genetec Q2FY2022 PAT Up by Sixfold
Company records strong Q2 performance of RM16.30 million, exceeding industry expectations
BANGI, Malaysia, Oct 25, 2021 - (ACN Newswire) - Genetec Technology Berhad ("Genetec" or the "Company"), a technology leader in providing customised full turnkey smart factory automation manufacturing lines, today announced that the Company recorded profit after tax ("PAT") of RM16.30 million for the second quarter ended 30 September 2021 ("Q2FY2022"), which is 515% higher than the PAT of RM2.65 million registered for the corresponding second quarter ended 30 September 2020 ("Q2FY2021").
Genetec also announced their proposal of a bonus issue of 661,564,800 new ordinary shares in Genetec ("Bonus Shares") on the basis of twelve (12) Bonus Shares for every one (1) existing ordinary share in Genetec ("Genetec Share" or "Share") held on an entitlement date to be determined later ("Proposed Bonus Issue"). The Entitlement Date will be determined and announced at a later date upon receipt of all relevant approvals for the Proposed Bonus Issue. In addition, for purposes of clarity, the actual number of Bonus Shares to be issued will depend on the total number of issued Shares on the Entitlement Date and is not intended to be implemented on a staggered basis. Further and final details will be announced upon receipt of all relevant approvals soon.
Genetec registered RM17.59 million in profit before tax ("PBT") for the quarter under review, which is 554% higher than the PBT of RM2.69 million recorded for Q2FY2021 while revenue of RM59.31 million is 53% higher than the RM38.67 million posted in Q2FY2021. Earnings per share stood at 31.25 sen (fully diluted) in Q2FY2022 compared to EPS of 6.18 sen in Q2FY2021.
For the first-half of the financial year ended 31 March 2022 ("1HFY2022"), the Company recorded 2884% higher PAT of RM24.50 million compared to the corresponding period of the previous financial year, when the Company posted PAT of RM821,000. PBT for 1HFY2022 stood at RM26.44 million, which is 2848% higher than the PBT of RM897,000 while revenue is 95% higher at RM99.59 million compared to RM51.10 million of the corresponding period of the previous financial year.
In their announcements the Company highlighted, "It has been an eventful year. Genetec's bonus issue proposal is part of our efforts to enhance trading liquidity of the Genetec shares, following the recent share price appreciation, as well as to reward existing shareholders on the back of the strong performance of the EV and energy storage divisions. The strong performances have contributed significantly to overall revenue amid steady demand for more sustainable modes of transport and energy. We expect the order book for the EV division to remain significant and to continue contributing to Genetec's financial performance in the coming quarters. As countries and companies step up their transition towards more sustainable and zero emission transport and energy solutions, we are confident that this growth trajectory will continue. It is well supported by the trifecta of global regulatory frameworks, new incentives to promote the adoption of EVs, and a fast-expanding range of EVs. Meanwhile, EV models are becoming more accessible as the ecosystem grows and battery costs drop further."
"While we have a more positive outlook as the global economy reopens amid higher vaccination rates, we remain cautious of spikes in COVID-19 infections that may result in supply-chain disruptions and affect consumer sentiment."
Source: Genetec Technology Bhd
Sectors: Daily Finance, Local Biz, Manufacturing
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
TOPVISION Launches Prospectus for Listing Transfer from LEAP to the ACE Market
Nov 27, 2024 05:53 JST
TOYOTA GAZOO Racing FULLY PREPARED FOR DAKAR 2025
Nov 26, 2024 17:55 JST
Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan
Nov 26, 2024 15:50 JST
Fujitsu develops Policy Twin, a new digital twin technology to maximize effectiveness of local government policies for solving societal issues
Nov 26, 2024 10:51 JST
TOYOTA GAZOO Racing reinforces WRC line-up with youth and experience for 2025
Nov 25, 2024 17:10 JST
Toyota Submits Progress Report on Recurrence Prevention Measures
Nov 25, 2024 15:43 JST
TOPVISION Launches Prospectus for Transfer Listing from LEAP to the ACE Market
Nov 25, 2024 15:00 JST
MHI Thermal Systems Receives Order from Aisan Industry for Aquifer Thermal Energy Storage System for Its New Anjo Plant
Nov 25, 2024 14:18 JST
Oracle Red Bull Racing Driver Max Verstappen Wins Fourth Consecutive F1 Drivers' World Championship
Nov 25, 2024 11:55 JST
Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Humacyte, Inc. (HUMA) - Deadline is January 17, 2025
Nov 22, 2024 11:00 JST
NaaS Q3 2024 Recap: Strategic Shifts and Tech Innovations for Growth
Nov 21, 2024 22:59 JST
Honda Unveils Demonstration Production Line for All-Solid-State Batteries Located in Sakura City, Tochigi Prefecture, Japan
Nov 21, 2024 15:35 JST
Deadline to Lead in Securities Fraud Lawsuit Against Humacyte, Inc. (HUMA) is January 17, 2025 - Contact Kaplan Fox & Kilsheimer LLP
Nov 21, 2024 09:00 JST
ALL Study Groups Using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study
Nov 20, 2024 23:05 JST
Start of Demonstration Test of Two-Phase Direct-to-Chip Cooling in the Air-Cooled Data Center
Nov 20, 2024 15:30 JST
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan
Nov 20, 2024 11:51 JST
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements
Nov 20, 2024 10:24 JST
Kingsoft Announces 2024 Third Quarter Results
Nov 19, 2024 18:54 JST
NTT and Olympus Joint Demonstration Shows IOWN APN's Low-latency Capability Can Be Used for Real-time Diagnosis and Treatment on a Remote Server to Realize World's First Cloud Endoscopy System
Nov 19, 2024 15:30 JST
Supercomputer Fugaku retains first place worldwide in HPCG and Graph500 rankings
Nov 19, 2024 09:02 JST
More Latest Release >>
Related Release
Genetec maintains stable and profitable performance on a lower Q1FY2025 revenue
November 27 2024 10:00 JST
Genetec's Consistent Performance Delivers Higher Overall Margins in Q4FY2024
May 28 2024 19:18 JST
Genetec Sets the Stage for Higher Growth Following a Strong Q3FY2024 Performance
February 27 2024 20:00 JST
Genetec Powers ahead with Steady Growth in Q2FY2024
November 29 2023 17:00 JST
Genetec's Q2FY2023 Performance Remains on Track
November 29 2022 17:00 JST
Genetec's Quarterly Performance Jumps by 126%
August 29 2022 18:00 JST
Genetec Scales New Heights with Highest Annual Profit to Date
May 26 2022 18:00 JST
Genetec Delivers Its Best Quarter to Date
January 26 2022 16:00 JST
More Press release >>